[Guillain-Barré syndrome. Current status]

Area of Science:

• Neuroimmunology
• Peripheral Nervous System Disorders
• Autoimmune Diseases

Background:

• Experimental allergic neuritis (EAN) closely resembles Guillain-Barré syndrome (GBS), supporting an immune-mediated etiology for GBS.
• Research efforts focus on identifying specific antigenic targets within peripheral nervous system myelin.
• The precise immune mechanisms, whether humoral or cellular, underlying GBS remain under investigation.

Purpose of the Study:

• To review studies identifying antigenic determinants of peripheral nervous system myelin.
• To present data supporting humoral or cellular immune mechanisms in EAN and GBS.
• To discuss the potential for long-term sequelae in GBS and evaluate therapeutic interventions.

Main Methods:

• Review of existing literature on experimental allergic neuritis and Guillain-Barré syndrome.
• Analysis of studies investigating myelin antigens and immune responses (humoral and cellular).
• Examination of clinical data regarding GBS progression, sequelae, and treatment outcomes.

Main Results:

• Strong evidence suggests GBS is an immune reaction, but the specific antigen is yet to be identified.
• Data are presented for both experimental and clinical evidence of immune involvement.
• Corticosteroid treatment has proven ineffective; controlled studies on plasmapheresis are in progress.

Conclusions:

• Guillain-Barré syndrome is likely an autoimmune disorder targeting peripheral nerve myelin.
• The exact antigen and dominant immune pathway (humoral vs. cellular) require further elucidation.
• GBS can result in unpredictable sequelae, and plasmapheresis shows therapeutic promise.